Label-free quantitative proteomics of CD133-positive liver cancer stem cells
2012
Background
CD133-positive liver cancer stem cells, which are characterized by their resistance to conventional chemotherapy and their tumor initiation ability at limited dilutions, have been recognized as a critical target in liver cancer therapeutics. In the current work, we developed a label-free quantitative method to investigate the proteome of CD133-positive liver cancer stem cells for the purpose of identifying unique biomarkers that can be utilized for targeting liver cancer stem cells. Label-free quantitation was performed in combination with ID-based Elution time Alignment by Linear regression Quantitation (IDEAL-Q) and MaxQuant.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
67
References
7
Citations
NaN
KQI